Getinge

Earnings Release • Apr 17, 2008

Reporting period January – March

• ♦ Orders received increased by 25% to SEK 4,673 million (3,737)
• ♦ Net sales increased by 20.3% to SEK 4,107 million (3,415)
• ♦ Profit before tax rose by 29% to SEK 369 million (286)
• ♦ Net profit increased by 31% to SEK 266 million (203)
• ♦ Earnings per share increased by 29.7% to SEK 1.31 (1.01)
• ♦ EBITA before restructuring rose by 36.7% to SEK 655 million (479)
• ♦ Acquisition of Boston Scientific's cardiac and vascular surgery divisions
• ♦ Continued strong profit forecasts for the year

Orders received	Demand in several of the Group's markets remained strong during the period. During the quarter, orders received grew organically by 10.6% and the volume growth was positive in all business areas. As in the preceding quarter, orders received remained positive in emerging markets and in North America.
	For Medical Systems, orders received increased organically by 11.7%. Development in North and Latin America was very strong, while orders received in Europe decreased somewhat.
	For Extended Care, the organic order growth amounted to a healthy 10.4%. With the exception of North America growth was generally positive.
	Infection Control's orders received grew organically by 9.4%. As with Medical Systems, orders received were strong or very strong in the various geographic regions, with the exception of Europe, where volumes were slightly declining.
Results	Consolidated profit before tax for the period amounted to SEK 369 million (286), an increase of 29%. The result for the quarter includes restructuring costs of SEK 23 million (51). EBITA, excluding restructuring costs, amounted to SEK 655 million (479) corresponding to a profit increase of 37%. The EBITA margin, excluding restructuring costs, amounted to 15.9% (14%) for the period and reflected the planned margin improvements within Extended Care and contributions from the divisions newly acquired from Boston Scientific. A negative currency impact of SEK 55 million has been charged against the quarter.

Outlook The outlook in terms of volume and demand for the Group's products and services is considered to be very good and the Group's order book remains at a high level.

Medical Systems still anticipates volume growth in excess of underlying market growth. The business area's investments in expanding the market organisation in emerging markets and strengthening the product range will contribute to volume growth. Continued expansion of production in the units in Turkey and China is strengthening competitiveness.

The acquisition of Boston Scientific's Cardiac and Vascular Surgery divisions, which are consolidated in the business area from the beginning of the year, contributes to profit growth and continued margin improvement. Integration costs totalling approximately SEK 85 million will, in their entirety, be charged against the current year and lead to cost savings of SEK 100 – 120 million per year from 2010. Excluding the integration costs, the acquisition is expected to contribute to the group's profit before tax during the current year.

In Extended Care, volume growth is expected to improve this year compared with last. Several new products will contribute to volume growth. Cost synergies from activities implemented in conjunction with the Huntleigh acquisition will contribute to profit growth, while integration costs will decline. At the beginning of 2008 the main emphasis of the Huntleigh integration will remain the identification of cost synergies, but the focus will shift to realising planned revenue synergies in the latter half of the year. Extended Care expects a significant strengthening of the EBITA margin during the year.

Infection Control also anticipates continued strong growth. The plan for the expansion of the market organisation within the key growth regions and an augmented product range will contribute to this development.

Exchange-rate changes will negatively impact earnings for the current year.

On the whole, the Group expects organic invoicing growth in line with 2007 levels. The EBITA margin remains strong, even excluding the cardiac and vascular surgery divisions from Boston Scientific.

Business area Medical Systems

Orders received

	2008		2007 Change adjusted fo r
Orders received per market	3 Mon		3 Mon curr.flucs.&co rp.acqs.
Europe	807	798	-2,8%
USA and Canada	619	239	15,1%
As ia and Australia	265	202	10,5%
Res t of the world	218	90	133,8%
Business area total	1 909	1 329	11,7%

Medical Systems' orders received increased organically by 11.7% for the period. In European markets, orders received were somewhat lower than for the same period last year. Orders received in German-speaking markets and in Scandinavia rose while other regions including Eastern Europe demonstrated lower orders received.

In North America, orders received were strong in the US as well as in the Canadian markets. The integration of Surgical Workplaces' organisation in the business area's US market company proceeded according to plan and without disruptions during the quarter.

The volume growth in Asian markets was generally good, particularly in India and China as well as the Middle East. Volume growth also remained strong in Latin America, especially in Brazil where large orders were registered.

Results

	2008	2007	Change	2007
	3 Mon	3 Mon		FY
Net sales, SEK m illion	1 786	1 273	40,3%	6 079
adjusted for currency flucs.& corp.acqs			8,1%
Gross profit	1 023	704	45,3%	3 112
Gross margin %	57,3%	55,3%	2,0%	51,2%
Operating cost, SEK m illion	-740	-505	46,5%	-2 079
EBITA before restructuring and integration costs EBITA margin %	331 18,5%	201 15,8%	64,7% 2,7%	1 040 17,1%
Restructuring and integration costs	-3	–	0,0%	–
EBIT	280	199	40,7%	1 033
EBIT margin %	15,7%	15,6%	0,1%	17,0%

The business area's EBITA amounted to SEK 331 million (201), an increase of 64.7%. The strong earnings growth was attributable to earnings contributions from the newly acquired cardiac and vascular divisions. The period was charged with restructuring costs amounting to SEK 3 million pertaining to the above-mentioned acquisition. The organic volume growth remained favourable for the period. The business area's EBITA margin, excluding restructuring costs, amounted to 18.5% (15.8).

Activities Integration of the acquisition of Boston Scientific's cardiac and vascular divisions

The integration of the new cardiac and vascular divisions, which were consolidated from January this year, proceeded according to plan during the first quarter. The initial integration work focused on developing and transferring a number of support functions that were historically provided by Boston Scientific, and transferring sales of primarily vascular surgery products from Boston Scientific's market organisation outside the US to Medical Systems' existing sales companies in the markets concerned. The business area estimates that it will be able to provide the required functions at a lower cost in the new structure, while sales under Medical Systems' management will be assigned greater focus and generate improved growth.

The business area also plans to realise the sales synergies which will lead to an organic growth increase of about 10% in the new Cardiovascular division from 2009. The key ingredients in this effort include distributing the division's Perfusion products through the new, strong sales organisation in the US and introducing and commercialising the products of the cardiac and vascular divisions to customers in Europe where Medical Systems market organisation is already strong. Endoscopic vessel harvesting products, in particular, have been deemed to have strong growth potential in markets outside the US.

In conjunction with the acquisition of the cardiac and vascular surgery divisions from Boston Scientific, the business area assessed that restructuring and integration costs would amount to SEK 100 million and that the costs would be divided into SEK 50 million this year and SEK 50 million in 2009. After careful analysis, the total integration cost was assessed to amount to approximately SEK 85 million, which in its entirety will be charged against the current year. Cost synergies resulting from the acquisition are expected to amount to SEK 100 – 120 million per year and will be visible in the results from 2010.

Jointly with management of the newly acquired cardiac surgery division, Medical Systems decided to discontinue the surgical ablation operations. These operations, which had sales of slightly more than SEK 50 million annually, had been operating at a loss for some time and the possibilities to generate profitable business in the long-term were deemed to be very small.

During the period, Medical Systems submitted a writ against Terumo pertaining to patent infringement of the business area's products for endoscopic vessel harvesting. The costs for a process against Terumo have been taken into consideration in the outlook for the operations.

Product development and product launches

An important cornerstone in Medical Systems' strategy is to actively maintain a distinct product leadership in the markets and areas in which it operates. With this in mind, continued major investments are made in

product development, with a focus on the Critical Care and Cardiovascular divisions.

Two important development projects within Critical Care have been in progress for some time.

NAVA, which comprises a new way to adjust ventilators and adapt the ventilator to the patient's needs, continues to generate major interest among users in a large number of markets. In the short term, focus is on introducing NAVA in additional markets while several studies are being conducted with the aim of demonstrating that the NAVA technology improves the quality of care and shortens medical treatment.

Flow-i, which is the division's new and innovative anaesthesia product, received major interest from potential users and decision-makers on the occasions when it was shown. In terms of volume, Flow-i will initially contribute to growth in the business area during 2009.

Several development projects are also being conducted in Cardiovascular's Perfusion area. The work on producing a new and uniform family of oxygenators is proceeding according to plan and means that all oxygenators will be based on the Quadrox platform in the future. The project for a new family of oxygenators is expected to be completed during the current year and will lead to improved performance and significantly lower manufacturing costs. The development of a new heartlung machine is proceeding according to plan and the product that is expected to be launched during 2010. As a subproject to the development of a new heart-lung machine, a more simple cardiac assist product is being developed to be used in emergencies to keep cardiac arrest patients alive for some time.

Production in China

Medical Systems' construction of a new production unit in Suzhou, China, is progressing according to plan and the unit will become operational during the second quarter of the year. The business area's collective production of ceiling service units for operating theatres will be transferred to the new unit during the year. In addition, the business area will transfer production of a more simple surgical table to the unit during the year.

Business area Extended Care

Orders received

	2008		2007 Change adjusted fo r
Orders received per market	3 Mon		3 Mon curr.flucs.&co rp.acqs.
Europe	1 068	877	14,1%
USA and Canada	409	387	-3,2%
Asia and Australia	149	81	32,7%
Rest of the world	23	17	9,9%
Business area total	1 649	1 362	10,4%

Extended Care's orders received developed well during the quarter and increased organically by 10.4%. Volume development for Huntleigh's product program was particularly strong. In Europe, several markets demonstrated good growth figures including Southern Europe and the UK.

In North America, orders received were somewhat weaker during the first part of the year. This was attributable to the US, which grew rapidly during 2007. Orders received in Canada continued to increase.

Volume development in markets outside Europe and North America was generally positive.

Results

	2008	2007	Change	2007
	3 Mon	3 Mon		FY
Net sales, SEK m illion	1 398	1 290	8,4%	6 009
adjusted for currency flucs.& corp.acqs			-2,3%
Gross profit	701	627	11,8%	2 775
Gross margin %	50,1%	48,6%	1,5%	46,2%
Operating cost, SEK m illion	-489	-462	5,8%	-1 894
EBITA before restructuring and integration costs	242	188	28,7%	998
EBITA margin %	17,3%	14,6%	2,7%	16,6%
Restructuring and integration costs	-18	-50	0,0%	-257
EBIT	194	115	68,7%	624
EBIT margin %	13,9%	8,9%	5,0%	10,4%

EBITA, excluding restructuring costs of SEK 18 million, amounted to SEK 242 million (188), an increase of 28.7%. The organic invoicing volume fell slightly during the period. The earnings growth was attributable to the cost savings in the wake of the Huntleigh acquisition. The effects of the production transfers implemented during 2007 are visible in the improved gross margin. Operating costs for the period also declined significantly

compared with the same period last year since Huntleigh was only included during the months of February and March.

Activities Integration of Huntleigh

As announced earlier, large parts of the Huntleigh integration pertaining to cost synergies in terms of the production structure and the market organisation were executed during 2007. During the quarter, negotiations with trade union representatives at the unit in Luton, UK, commenced with the aim of transferring the remaining production to the business area's production unit in Suzhou, China, which is under construction. Production at the unit in Suzhou is expected to be deployed at the end of the third quarter of the year and will lead to further savings.

During the quarter, Extended Care divested its Renray operations with its registered office in Winsford. Renray, with sales of approximately SEK 120 million was included in the Huntleigh acquisition and conducts the manufacture and sale of furniture for institutions for the care of the elderly. The operation was not deemed to be part of the business area's future core operations. In the past three years, Renray has generated an average loss of SEK 9 million annually. Renray's management group was the buyer of the company.

In addition, an agreement was signed during the period to divest the cardiology business that was included in the Huntleigh acquisition. The business had sales of slightly more than SEK 30 million annually and will be sold to Swiss Schiller AG. Both Renray and the cardiology operation will be sold at the Group's carrying amount for the units and will consequently not generate a capital gain or loss.

During the second half of the current year, the focus will be on developing revenue synergies that are expected to contribute to a stable organic volume growth in line with the growth target of 7% that was established and applies from 2009.

The business area is well positioned to realise the cost synergies announced earlier, which will exceed SEK 300 million per year from 2009. Integration costs are estimated to amount to approximately SEK 400 million, of which, SEK 257 million was already utilised during 2007 and the remaining approximately SEK 140 – 150 million will essentially be charged against the current year.

Product development and launches

An important part of Extended Care's ambitions to increase organic growth and strengthen competitiveness is to conduct active product development. Within the framework of the profitability target that was announced, the business area intends to significantly increase investments in product development in coming years. During the current year, 15 to 20 new products and major product upgrades will be launched.

The business area's new product, Wound Assist, which is used for the treatment of wounds that are difficult to heal and referred to as Negative Pressure Wound Therapy (NPWT), is proceeding according to plan. Marketing activities are still focused on the UK and Germany in order to compile customer feedback prior to a wider launch primarily in other European markets. Wound Assist is assessed to have the potential to

take a significant share of markets outside the US, where the business area has long-term and extensive relationships with the most important decision makers. The NPWT market is one of the largest and most rapidly growing areas in advanced wound-care products.

Business area Infection Control

Orders received

	2008		2007 Change adjusted fo r
Orders received per market	3 Mon		3 Mon curr.flucs.&co rp.acqs.
Europe	606	626	-3,2%
USA and Canada	324	300	18,3%
Asia and Australia	131	110	17,8%
Rest of the world	54	10	433,7%
Business area total	1 115	1 046	9,4%

The business area's orders received increased organically by a healthy 9.4%. As with Medical Systems, volumes declined somewhat in the European market. The volume decline was due to low levels of orders received in Russia and Eastern Europe and to a lesser degree Southern Europe, while other European markets demonstrated better orders received.

In the North American market, growth in orders received was very solid in both the US and Canada. The streamlining of Getinge Inc into an Infection Control company and the transfer of Surgical Workplaces to Medical Systems' marketing company in the US were implemented with retained marketing activities.

Orders received from emerging markets outside Europe were generally very strong, particularly in Asia and Latin America.

Results

	2008	2007	Change	2007
	3 Mon	3 Mon		FY
Net sales, SEK m illion	924	852	8,5%	4 357
adjusted for currency flucs.& corp.acqs			11,6%
Gross profit	352	333	5,7%	1 659
Gross margin %	38,1%	39,1%	-1,0%	38,1%
Operating cost, SEK m illion	-273	-248	10,1%	-1 034
EBITA before restructuring and integration costs	83	89	-6,7%	640
EBITA margin %	9,0%	10,4%	-1,4%	14,7%
Restructuring and integration costs	-1	0	0,0%	0
EBIT	78	85	-8,2%	625
EBIT margin %	8,4%	10,0%	-1,6%	14,3%

The business area's EBITA declined somewhat compared with the same period last year and amounted to SEK 83 million (89). Invoicing growth was good while gross margin was negatively impacted by exchange-rate effects. The higher costs for the period were primarily attributable to the planned development of the marketing organisations outside Europe and to strengthening the management of the business area.

Activities New organisation in US

The new organisation for the business area's US operations that was mentioned in the preceding report was efficiently implemented during the quarter. The change, which means that Getinge Inc will be streamlined to focus solely on the infection control market, is expected to lead to increased focus and eventually more rapid growth and increased market share.

Continued streamlining of the production structure

During the quarter, Infection Control announced that it intends to relocate production of sterilizers at the plant in Peiting, Germany to Getinge's factory in Getinge. The decision is a step in the business area's ambition to reduce the number of production units and to increase the specialisation of the remaining units. The production of disinfection products at the unit in Peiting will remain. Costs for the proposed measures will be charged against the year's earnings in an amount of SEK 4 million and are expected to result in annual savings of SEK 2 million from 2009.

Other information

Accounting	This interim report was prepared for the Group in accordance with the IAS 34 Interim Financial Reporting and for the Parent Company, in accordance with the Annual Accounts Act. The accounting and calculation principles used in the interim report are identical to those used in the most recent annual report. This report is unaudited.
Rights issue	As previously announced Getinge's rights issue that generated the group approximately SEK 1 514 million before issue costs was oversubscribed. During April, the rights issue was registered with the Swedish Companies Registration Office and the last day for trading with interim shares (BTA) was 8 April 2008. The new shares carry the right to the dividend of SEK 2.40 per share that is proposed by the board.
Risk management	Political decisions altering the healthcare reimbursement system represent the single greatest risk to the Getinge Group. The risk to the Group as a whole is limited by the fact that Getinge is active in a large number of countries. The Group's operational risks are limited, since as a rule its customers' operations are funded directly or indirectly from public funds. The Group's Risk Management team works continuously to minimise the risk of production disruptions. Financial risk management Getinge is exposed to a number of financial risks in its operations. "Financial risks" refer primarily to risks related to currency and interest rates as well as credit risks. Risk management is regulated by a financial policy established by the Board of Directors. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with Group management and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks, and credit and counterparty risks.
Forward-looking information	This report contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.
Next report	The next report from the Getinge Group (second quarter of 2008) will be published on 14 July 2008.
Teleconference	A teleconference will be held today at 2:00 p.m. Swedish time. To participate, please call: from Sweden +46(0)8 50 520 110 , password: Getinge outside Sweden +44(0)20 7162 0025, password: Getinge
	A recorded version of the conference will be available for five working days on the following numbers: Sweden: +46 (0)8 505 203 33, access code: 791923 UK: +44 (0)20 7031 4064, access code: 791923

The Board of Directors and President ensure that the interim report provides a true and fair overview of the Parent Company and the Group's operations, position and earnings and describes the material risks faced by the Parent Company and the Group.

Getinge, 17April 2008

Carl Bennet Chairman	Johan Bygge	Rolf Ekedahl
Arild Karlsson	Carola Lemne	Margareta Norell Bergendahl
Bo Sehlin	Johan Stern	Johan Malmquist CEO

Getinge AB Box 69, 310 44 Getinge Telephone 035-15 55 00. Telefax 035-549 52 e-mail info@getinge.com Corporate Registration Number 556408-5032 www.getingegroup.com

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.

Consolidated Income statement

	2008	2007	Change	2007
SEK millio n	3 Mon	3 Mon		FY
Net sales	4 107	3 415	20,3%	16 445
Cost of goods sold	-2 031	-1 751	16,0%	-8 899
Gross profit	2 076	1 664	24,8%	7 546
Gross margin	50,5%	48,7%	1,8%	45,9%
Selling expenses	-916	-715	28,1%	-3 072
Adm inistrative expenses	-437	-390	12,1%	-1 604
Research & developm ent costs 1 Restructuring and integration	-145	-102	42,2%	-335
costs	-23	-51	-54,9%	-257
Other operating incom e and
expenses	-4	-6	-33,3%	4
Operating profit 2	551	400	37,8%	2 282
Operating margin	13,4%	11,7%	1,7%	13,9%
Financial net	-182	-114		-507
Profit before tax	369	286	29,0%	1 775
Taxes	-103	-83		-514
Net profit	266	203	31,0%	1 261
Attributable to:
Parent com pany's shareholders	265	203		1 260
Minority interest	1	0		1
Net profit	266	203		1 261
Earnings per share, SEK 3	1,31	1,01	29,7%	6,24
1 Developm ent costs totalling SEK 85 (55) m illion have b een capitalised during the quarter.

2 Operating profit is charged with

-81	-28	-139
-27	-18	-82
-119	-96	-463
-227	-142	-684

3 There are no dilutions

Quarterly results

	2006	2006	2006	2006	2007	2007	2007	2007	2008
SEK millio n	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1
Net sales	2 975	3 148	2 883	3 995	3 415	4 029	3 844	5 157	4 107
Cost of goods sold	-1 644	-1 726	-1 618	-2 120	-1 751	-2 206	-2 140	-2 802	-2 031
Gross profit	1 331	1 422	1 265	1 875	1 664	1 823	1 704	2 355	2 076
Operating cost	-1 020	-1 004	-898	-1 035	-1 264	-1 327	-1 351	-1 322	-1 525
Operating profit	311	418	367	840	400	496	353	1 033	551
Financial net	-49	-54	-53	-52	-114	-130	-132	-131	-182
Profit before tax	262	364	314	788	286	366	221	902	369
Taxes	-71	-98	-85	-215	-83	-106	-64	-261	-103
Profit after tax	191	266	229	573	203	260	157	641	266

Consolidated Balance sheet

	2008	2007	2007
Assets SEK millio n	31 Mar	31 Mar	31 Dec
Intangible fixed assets	13 953	10 423	10 396
Tangible fixed assets	2 605	2 353	2 327
Financial assets	968	751	755
Stock-in-trade	3 271	2 956	2 913
Current receivables	5 380	4 794	5 706
Cash and cash equivalents	1 610	931	894
Total assets	27 787	22 208	22 991
Shareholders' equity & Liabilities
Shareholders' equity	7 851	6 267	6 623
Long-term liabilities	15 163	11 442	11 908
Current liabilities	4 773	4 499	4 460
Total Equity & Liabilities	27 787	22 208	22 991

Consolidated Cash flow statement

	2008	2007	2007
SEK millio n	3 Mon	3 Mon	FY
Current activities
Operating profit	551	400	2 282
Adjustm ent for item s not included in cash flow	170	202	761
Financial item s	-182	-114	-507
Taxes paid	-204	-125	-528
Cash flow before changes in working capital	335	363	2 008
Changes in working capital
Stock-in-trade	-326	-385	-341
Rental equipm ent	-34	-11	-168
Current receivables	432	477	-458
Current operating liabilities	97	188	287
Cash flow from operations	504	632	1 328
Investm ents
Acquisition of subsidiaries	-4 894	-5 514	-5 622
Investm ents in intangible fixed assets	-90	-60	-348
Investm ents in tangible fixed assets	-120	-82	-467
Disposal of tangible fixed assets	0	5	34
Cash flow from investments	-5 104	-5 651	-6 403
Financial activities
Change in interest-bearing debt	3 182	4 195	4 518
Change in long-term receivables	59	1 225	1 249
Minority redem ption	1 492,0	–	0
Dividend paid	0	0	-444
Cash flow from financial activities	4 733	5 420	5 323
Cash flow for the period	133	401	248
Cash and cash equivalents at begin of the year	894	673	673
Translation differences	583	-143	-27
Cash and cash equivalents at end of the period	1 610	931	894

Operating cash flow statement

	2008	2007	2007
SEK millio n	3 Mon	3 Mon	FY
Business activities
Operating profit	551	400	2 282
Restructuring costs	23	51	257
Adjustm ent for item s not included in cash flow	185	172	695
	759	623	3 234
Changes in operating capital
Stock-in-trade	-326	-385	-341
Rental equipm ent	-34	-11	-168
Current receivables	432	477	-458
Current liabilities	97	188	287
Operating cash flow	928	892	2 554
Restructuring cost cash generated	-38	-21	-190
Operating cash flow after restructuring
cost	890	871	2 364

Consolidated Net interest-bearing debt

	2008	2007	2007
SEK millio n	31 Mar	31 Mar	31 Dec
Debt to credit ins titutions	12 688	9 119	9 454
Provis ions for pens ions, interest-bearing	1 750	1 921	1 805
Less liquid funds	-1 610	-931	-894
Net interest-bearing debt	12 828	10 109	10 365

Changes to shareholders' equity

	2008	2007	2007
SEK millio n	31 Mar	31 Mar	31 Dec
Shareholders' equity – opening balance	6 623	6 005	6 005
Dividend distributed			-444
Change of reserve hedge accounting	6	-63	-58
Translation differences	-536	122	-141
Net profit	266	203	1 261
Shareholders' equity – closing balance	7 851	6 267	6 623
Attributable to:
Parent com pany's shareholders	7 826	6 241	6 598
Minority interest	25	26	25
Total shareholders' equity	7 851	6 267	6 623

Key figures

	2008		2007 Change	2006	2007
	3 Mon	3 Mon		3 mån	FY
Orders received, SEK m illion	4 673	3 737	25,0%	3 314	16 519
adjusted for currency flucs.& corp.acqs			10,6%
Net sales, SEK m illion	4 107	3 415	20,3%	2 975	16 445
adjusted for currency flucs.& corp.acqs			4,6%
EBITA before restructuring- and integration cos ts EBITA m argin before restructuring- and	655	479	36,7%	320	2 678
integration costs	15,9%	14,0%	1,9%	10,8%	16,3%
Restructuring and integration cos ts	23	51	0,0%	–	257
EBITA	632	428	47,7%	320	2 421
EBITA m argin	15,4%	12,5%	2,9%	10,8%	14,7%
Earnings per share after full tax, SEK	1,31	1,01	29,7%	0,93	6,24
Num ber of shares, thousands		201 874 201 874			201 874 201 874
Operating capital, SEK m illion	16 542	10 223	61,8%	9 903	10 778
Return on operating capital, per cent	15,6%	19,3%	-3,7%	18,5%	19,7%
Return on equity, per cent	20,1%	22,1%	-2,0%	22,3%	20,3%
Net debt/equity ratio, m ultiple	1,63	1,61	0,02	0,86	1,57
Interest cover, m ultiple	4,1	7,2	-3,1	8,2	4,3
Equity/ass ets ratio, per cent	28,3%	28,2%	0,1%	38,8%	28,8%
Equity per share, SEK	38,77	30,92	25,4%	27,14	32,68
Num ber of em ployees at the period's end	11 090	10 343	7,2%	7 382	10 358

Income statement for the parent company

	2008	2007	2007
M kr	3 Mon	3 Mon	Helår
Adm inistrative expenses	-25	-29	-67
Operating profit	-25	-29	-67
Financial net	203	-22	542
Profit after financial items	178	-51	475
Appropriations	–	–	0
Profit vefore tax	178	-51	475
Taxes	-50	12	96
Net profit	128	-39	571

Balance sheet for the parent company

	2008	2007	2007
Assets SEK million	31 Mar	31 Mar	31 Dec
Tangible fixed assets	11	14	12
Shares in group companies	4 767	3 476	4 120
Long-term financial receivables	40	49	41
Deferred tax asset	86	–	86
Receivable from group companies	16 077	12 135	13 033
Short-term receivables	580	167	65
Total assets	21 561	15 841	17 357
Shareholders' equity & Liabilities
Shareholders' equity	5 449	3 606	3 829
Long-term liabilities	11 508	8 223	7 523
Current liabilities	4 604	4 012	6 005
Total Equity & Liabilities	21 561	15 841	17 357

Information regarding changes in the parent company during the period January to March 2008

Income Statement	At the end of the period assets and liabilities in foreign currencies are revalued to the rates at the balance sheet date and an unrealised profit of SEK 180 million is included in the quarter's financial net figure.
Balance sheet	At the end of the period, the equity from the company's new share issue of approximately SEK 1 500 million was used to repay bank liabilities.
	During the first quarter of 2008 Boston Scientific's cardiac and vascular surgery divisions were acquired for a price of USD 750 million (SEK 4 851 million). The increase in the parent company's long-term liabilities is largely due to the financing of the acquisition.

Companies acquired in 2008

Boston Scientific's Cardiac and Vascular Surgery divisions

In January 2008, Boston Scientific's Cardiac and Vascular Surgery divisions were acquired. The divisions operate within the areas of endoscopic vessel harvesting, anastomosis, stabilisers and instrument for surgery on beating hearts and vessel implants. The total acquisition price amounted to approximately USD 750 million (SEK 4,851). The acquisition was reported according to the acquisition method. Acquisition costs in conjunction with the acquisition amounted to SEK 45 million.

Acquired net assets and goodwill in connection with the acquisition

	Balance sheet at
	time of	Adjustments to
Net assets	acquisition	fair value	Fair value
Intangible assets	2	1 947	1 949
Tangible fixed assets	351	45	396
Stock-in-trade	163		163
Other current assets	239		239
Provisions	-170		-170
Short-term liabilities	-138	-45	-183
	447	1 947	2 394
Goodwill			2 457
Total acquisition with cash and cash equivalents			4 851
Net outflow of cash and cash equivalents due to acquisition			4 851

Goodwill generated in connection with the transaction is principally attributable to synergies in terms of customer relationship's, geography, production and sales and distribution.

The acquired divisions from Boston Scientific are included in Getinge's sales and operating profit from 1 January 2008.

It is not practical to disclose the profits for the acquired business from the acquisition date due to the integration work that has been conducted during the period.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortisation of intangible assets identified in
	conjunction with corporate acquisitions.
BRIC	Brazil, Russia, India, China